Monday, May 16, 2016
A subsidiary of Jazz Pharmaceuticals has acquired 100% of the shares of Alizé Pharma II. This all-cash transaction closed in March 2016. The deal is valued at up to €18 million ($20.4 million), including an upfront payment of €8 million and potential payments of up to €10 million related to regulatory milestones. The transaction did not involve the transfer of any employees from the Alizé Pharma group to Jazz Pharmaceuticals.